Incyte has secured European Commission approval for povorcitinib, brand name Povofortay, in 45 mg and 75 mg strengths for eligible adults with moderate to severe hidradenitis suppurativa (HS), marking the first approval for the molecule and the EU's first and only once-daily oral treatment in this indication.
The selective JAK1 inhibitor was supported by the pivotal STOP-HS1 and STOP-HS2 trials, which met the HiSCR50 primary endpoint at week 12 across both doses in the overall intent-to-treat population and in post-anti-TNF patients, with durable responses sustained to week 54 where 71.4% of patients achieved HiSCR50, 57% reached HiSCR75 and 29% attained HiSCR100. Beyond lesion reduction, the 54-week data showed meaningful gains in skin pain, fatigue and quality-of-life measures, with a safety profile consistent with prior readouts and no new signals.
Incyte partnered with China Medical System in 2024 for Greater China and 11 Southeast Asian markets, and a US BLA filing targets a 2027 first-quarter launch.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation